Sugi Predict

Sugi Predict / Compounds / SCHEMBL2482883

SCHEMBL2482883

SCHEMBL2482883

Cc1nccn1-c1ccc(Nc2nc3c(c(Cc4ccccc4F)n2)CNCC3)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 4/20 0.36
▸ HTR2B P41595 3/20 0.36
▸ STAT6 P42226 2/20 0.35
▸ PTK2 Q05397 2/20 0.34
▸ EGFR P00533 1/20 0.34
▸ NR3C2 P08235 2/20 0.33
▸ VCP P55072 1/20 0.33
▸ HTR2A P28223 3/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ PORCN Q9H237 1/20 0.33
▸ BRD4 O60885 1/20 0.32
▸ MCHR1 Q99705 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ SYK P43405 1/20 0.31
▸ AXL P30530 2/20 0.31
▸ TYRO3 Q06418 2/20 0.31
▸ MERTK Q12866 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480963 0.88 HTR2C (0.39) HTR2CHTR2BVCPHTR2ACYP3A4
SCHEMBL2448042 0.85 ROCK2 (0.38) STAT6PTK2EGFRNR3C2CYP3A4
SCHEMBL2482372 0.84 TUBB4A (0.37) HTR2CHTR2BSTAT6EGFRHTR2A
SCHEMBL2447040 0.83 NTRK1 (0.37) HTR2CHTR2BSTAT6PTK2EGFR
SCHEMBL2446860 0.82 CREBBP (0.38) STAT6PTK2NR3C2CYP3A4CYP2D6
SCHEMBL2477084 0.82 PDCD1 (0.38) STAT6EGFRNR3C2CYP3A4CYP2D6
SCHEMBL2448106 0.82 NR3C2 (0.38) STAT6PTK2NR3C2CYP3A4CYP2D6
SCHEMBL2484835 0.81 SYK (0.37) HTR2CEGFRHTR2ACYP3A4CYP2D6
SCHEMBL2446003 0.81 HTR2A (0.40) HTR2CSTAT6PTK2HTR2ACYP3A4
SCHEMBL2444641 0.80 SYK (0.39) KDRSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 — — EP disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 — — WO disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 HTR2C 963/4885HTR2B 428/4885STAT6 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.